iShares Genomics Immunology and Healthcare ETF
iShares Genomics Immunology and Healthcare ETF reported 47 holdings worth US$191M as of Jul 31, 2026 (Form N-PORT)
As of Jul 31, 2026 · Filed Sep 23, 2026
iShares Genomics Immunology and Healthcare ETF reported 47 holdings worth US$191M as of Jul 31, 2026. Largest: Bayer Ag, Twist Bioscience Corporation and Revolution Medicines, Inc. Filed Sep 23, 2026 (Form N-PORT).
- Holdings
- 47
- Value as reported
- US$191M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Bayer Ag | 166K | US$9.18M | 4.8% |
| Twist Bioscience Corporation | 99,937 | US$9.15M | 4.8% |
| Revolution Medicines, Inc. | 46,352 | US$8.69M | 4.6% |
| Regeneron Pharmaceuticals, Inc. | 10,887 | US$8.3M | 4.4% |
| Genmab A/s | 28,069 | US$8.08M | 4.2% |
| Incyte Corporation | 67,570 | US$8.08M | 4.2% |
| Moderna, Inc. | 146K | US$7.99M | 4.2% |
| Takeda Pharmaceutical Co. Ltd. | 225K | US$7.73M | 4.0% |
| Merck & Company, Inc. | 57,270 | US$7.46M | 3.9% |
| Vertex Pharmaceuticals Incorporated | 15,481 | US$7.39M | 3.9% |
| Roche Holding Ltd | 16,796 | US$7.34M | 3.8% |
| Ipsen Sa | 37,928 | US$7.33M | 3.8% |
| Exelixis, Inc. | 131K | US$6.96M | 3.6% |
| Gsk Plc | 267K | US$6.93M | 3.6% |
| Sanofi Sa | 76,788 | US$6.61M | 3.5% |
| Ideaya Biosciences, Inc. | 180K | US$6.41M | 3.4% |
| Immunitybio, Inc. | 817K | US$5.86M | 3.1% |
| Arcus Biosciences, Inc. | 182K | US$5.12M | 2.7% |
| Caris Life Sciences, Inc. | 266K | US$4.17M | 2.2% |
| Ono Pharmaceutical Co., Ltd. | 245K | US$3.65M | 1.9% |
| Iovance Biotherapeutics, Inc. | 842K | US$3.43M | 1.8% |
| Nuvation Bio Inc. | 536K | US$3.39M | 1.8% |
| Crispr Therapeutics Ag | 62,247 | US$2.99M | 1.6% |
| Abcellera Biologics Inc. | 509K | US$2.91M | 1.5% |
| Vir Biotechnology, Inc. | 289K | US$2.51M | 1.3% |
| Novavax, Inc. | 340K | US$2.49M | 1.3% |
| Janux Therapeutics, Inc. | 124K | US$1.88M | 0.99% |
| Sunshine Lake Pharma Co., Ltd. Class H | 352K | US$1.87M | 0.98% |
| Corvus Pharmaceuticals, Inc. | 137K | US$1.82M | 0.95% |
| Personalis, Inc. | 134K | US$1.7M | 0.89% |
| Kura Oncology, Inc. | 186K | US$1.68M | 0.88% |
| Genfleet Therapeutics (shanghai), Inc. Class H | 419K | US$1.48M | 0.78% |
| Rigel Pharmaceuticals, Inc. | 38,807 | US$1.43M | 0.75% |
| Cytomx Therapeutics, Inc. | 376K | US$1.17M | 0.61% |
| Verastem, Inc. | 179K | US$1.04M | 0.54% |
| Alvotech | 245K | US$1.01M | 0.53% |
| Design Therapeutics, Inc. | 81,808 | US$996K | 0.52% |
| Xencor, Inc. | 48,671 | US$984K | 0.52% |
| Intellia Therapeutics, Inc. | 91,888 | US$981K | 0.51% |
| Shanghai Henlius Biotech, Inc. Class H | 136K | US$964K | 0.51% |
| Ocugen, Inc. | 724K | US$890K | 0.47% |
| Pacific Biosciences Of California, Inc. | 622K | US$871K | 0.46% |
| Valneva Se | 349K | US$866K | 0.45% |
| Ginkgo Bioworks Holdings, Inc. | 101K | US$820K | 0.43% |
| Abclon, Inc. | 34,319 | US$470K | 0.25% |
| Prime Medicine, Inc. | 65,480 | US$191K | 0.10% |
| Guangzhou Innogen Pharmaceutical Group Co Ltd Class H | 0 | US$0 | 0.00% |
Source
View original at SEC
Related